FDA updates Merck's Covid-19 pill EUA and reaffirms it should only be used as a last resort

The FDA recently revised the EUA for Merck’s Covid-19 pill molnupiravir, explaining that it should only be used as a last line of defense if other treatments are available, including Pfizer’s pill Paxlovid, which posted 89% final efficacy results in the NEJM this week. Regulators also said other more highly efficacious infused drugs, including GlaxoSmithKline’s sotrovimab and Gilead’s remdesivir, should be used before molnupiravir.